Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?

被引：2
|
作者：
Poletajew, Slawomir [1 ]
Krajewski, Wojciech [2 ]
Kryst, Piotr [1 ]
机构：
[1] Ctr Postgrad Med Educ, Dept Urol 2, 80 Ceglowska St, PL-00809 Warsaw, Poland
[2] Wroclaw Med Univ, Dept Urol & Oncol Urol, Wroclaw, Poland
来源：
TRANSLATIONAL ANDROLOGY AND UROLOGY | 2020年 / 9卷 / 06期
关键词：
CISPLATIN-INELIGIBLE PATIENTS; PD-1; BLOCKADE; UROTHELIAL CARCINOMA; CLINICAL-RESPONSE; SOLID TUMORS; SINGLE-ARM; MULTICENTER; SENSITIVITY; EXPRESSION; GUIDELINES;
D O I：
10.21037/tau-20-907
中图分类号：
R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
摘要：
引用
收藏
页码：2479 / 2482
页数：4
相关论文
共 50 条
  • [41] The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors
    Corbellari, Riccardo
    Nadal, Lisa
    Villa, Alessandra
    Neri, Dario
    De Luca, Roberto
    ANTI-CANCER DRUGS, 2020, 31 (08) : 799 - 805
  • [42] Combination therapy with immune check point inhibitors and acute kidney injury
    Valentin, Amalie
    Moller, Anne Kirstine Hundahl
    Palshof, Jesper Andreas
    Broberg, Bo
    Gravesen, Eva
    Svane, Inge Marie
    Hansen, Ditte
    ACTA ONCOLOGICA, 2023, 62 (02) : 121 - 125
  • [43] Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer
    Benzon, Benjamin
    Glavaris, Stephanie A.
    Simons, Brian W.
    Hughes, Robert M.
    Ghabili, Kamyar
    Mullane, Patrick
    Miller, Rebecca
    Nugent, Katriana
    Shinder, Brian
    Tosoian, Jeffrey
    Fuchs, Ephraim J.
    Tran, Phuoc T.
    Hurley, Paula J.
    Vuica-Ross, Milena
    Schaeffer, Edward M.
    Drake, Charles G.
    Ross, Ashley E.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (01) : 126 - 136
  • [44] Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer
    Benjamin Benzon
    Stephanie A. Glavaris
    Brian W. Simons
    Robert M. Hughes
    Kamyar Ghabili
    Patrick Mullane
    Rebecca Miller
    Katriana Nugent
    Brian Shinder
    Jeffrey Tosoian
    Ephraim J. Fuchs
    Phuoc T. Tran
    Paula J. Hurley
    Milena Vuica-Ross
    Edward M. Schaeffer
    Charles G. Drake
    Ashley E. Ross
    Prostate Cancer and Prostatic Diseases, 2018, 21 : 126 - 136
  • [45] Venous thromboembolism in patients with advanced non-small cell lung cancer treated with immune check-point inhibitors: a retrospective cohort study
    Icht, O.
    Darzi, N.
    Landman, Y.
    Reinhorn, D.
    Shochat, T.
    Jacobi, O.
    Rotem, O.
    Dudnik, E.
    Spectre, G.
    Raanani, P.
    Zer, A.
    Leader, A.
    THROMBOSIS RESEARCH, 2021, 200 : S49 - S50
  • [46] Immune check point inhibitors: A promising therapeutic approach in oral cancer
    Revathi, Duraisamy
    Dhanraj, Ganapathy
    Ashok, V.
    ORAL ONCOLOGY, 2022, 132
  • [47] Neurologic Immune-related Adverse Events Associated with Check-point Inhibitors: A Case Study and Systematic Review of the Literature
    Juster-Switlyk, Kelsey
    Johnson, Nicholas
    NEUROLOGY, 2018, 90
  • [48] Immune check point inhibitors (ICIs) in cancer therapy: An experience from a resource poor and developing country
    Naseer, M.
    Patel, A.
    Anand, A.
    Panchal, H.
    Parikh, S.
    Sajjan, K.
    Madabhavi, I. V.
    Pareek, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1440 - S1440
  • [49] Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
    Nero, Camilla
    Ciccarone, Francesca
    Pietragalla, Antonella
    Duranti, Simona
    Daniele, Gennaro
    Salutari, Vanda
    Carbone, Maria Vittoria
    Scambia, Giovanni
    Lorusso, Domenica
    CANCERS, 2021, 13 (06) : 1 - 13
  • [50] Impact of Nutritional Status on Neutrophil-to-Lymphocyte Ratio as a Predictor of Efficacy and Adverse Events of Immune Check-Point Inhibitors
    Sue, Masahiko
    Takeuchi, Yasuto
    Hirata, Shoichiro
    Takaki, Akinobu
    Otsuka, Motoyuki
    CANCERS, 2024, 16 (10)
12345